(Q42837959)

8 November 2017

Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment (English)

1 reference

8 November 2017

9

A Tefferi

1 reference

8 November 2017

5

M R Litzow

1 reference

8 November 2017

N Gangat

1

1 reference

8 November 2017

M M Patnaik

2

1 reference

8 November 2017

K Begna

3

1 reference

8 November 2017

A Al-Kali

4

1 reference

8 November 2017

R P Ketterling

6

1 reference

8 November 2017

C A Hanson

7

1 reference

8 November 2017

A D Pardanani

8

1 reference

8 November 2017

8 April 2016

1 reference

8 November 2017

1 reference

8 November 2017

6

1 reference

8 November 2017

e414

1 reference

Creative Commons Attribution 4.0 International

8 November 2017

start time

1 April 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/bcj.2016.23

0 references

cites work

Myelodysplastic syndromes: Contemporary review and how we treat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Revised international prognostic scoring system for myelodysplastic syndromes

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4855255

16 August 2018

Identifiers

DOI

10.1038/BCJ.2016.23

1 reference

Dimensions Publication ID

8 November 2017

0 references

1 reference

8 November 2017

PubMed publication ID

27058229

1 reference